The 7 major pemphigus vulgaris markets reached a value of US$ 265.3 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 519.4 Million by 2034, exhibiting a growth rate (CAGR) of 7.75% during 2023-2034.
The pemphigus vulgaris market has been comprehensively analyzed in this report titled "Pemphigus Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pemphigus vulgaris is a rare autoimmune disorder that affects the skin and mucous membranes, causing painful blistering and erosions. It can affect in various areas of the body, such as the mouth, throat, nose, genitals, abdomen, etc. The symptoms of the condition typically include the formation of fragile, fluid-filled blisters, leaving open sores that are painful and prone to infection. Various other indications are itching, burning, pain in affected areas, fever, fatigue, weight loss, etc. The ailment is diagnosed through a combination of clinical examination, skin biopsy, and blood tests. The healthcare professionals will typically begin by conducting a physical exam to assess the extent and severity of the blistering and erosions. They may also take a biopsy of the affected skin or mucous membrane to look for characteristic changes in the cells and tissues. Additionally, blood tests may be ordered to detect the presence of antibodies associated with pemphigus vulgaris.
The rising cases of immune system malfunction in which antibodies attack the proteins that hold skin cells together are primarily driving the pemphigus vulgaris market. Additionally, the escalating usage of various medications, such as nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, penicillamine, etc., which aid in triggering the onset of the ailment, is also propelling the market growth. Besides this, the widespread adoption of immunosuppressive agents in conjunction with corticosteroids to control the immune system and prevent the formation of new blisters is creating a positive outlook for the market. Moreover, the emerging popularity of plasmapheresis for treating severe cases of disease that do not respond to other treatments is acting as another significant growth-inducing factor. This procedure is used to remove autoantibodies and other immune system components that contribute to the development of the ailment. Furthermore, the rising usage of indirect immunofluorescence for diagnosing the disorder, which involves using fluorescent antibodies to detect the presence of autoantibodies, is also augmenting the market growth. Apart from this, the escalating demand for intravenous immunoglobulin therapy among patients with refractory disease or who are unable to tolerate systemic corticosteroids is expected to drive the pemphigus vulgaris market during the forecast period.
This report provides an exhaustive analysis of the pemphigus vulgaris market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pemphigus vulgaris and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pemphigus vulgaris market in any manner.
The pemphigus vulgaris market has been comprehensively analyzed in this report titled "Pemphigus Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pemphigus vulgaris is a rare autoimmune disorder that affects the skin and mucous membranes, causing painful blistering and erosions. It can affect in various areas of the body, such as the mouth, throat, nose, genitals, abdomen, etc. The symptoms of the condition typically include the formation of fragile, fluid-filled blisters, leaving open sores that are painful and prone to infection. Various other indications are itching, burning, pain in affected areas, fever, fatigue, weight loss, etc. The ailment is diagnosed through a combination of clinical examination, skin biopsy, and blood tests. The healthcare professionals will typically begin by conducting a physical exam to assess the extent and severity of the blistering and erosions. They may also take a biopsy of the affected skin or mucous membrane to look for characteristic changes in the cells and tissues. Additionally, blood tests may be ordered to detect the presence of antibodies associated with pemphigus vulgaris.
The rising cases of immune system malfunction in which antibodies attack the proteins that hold skin cells together are primarily driving the pemphigus vulgaris market. Additionally, the escalating usage of various medications, such as nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, penicillamine, etc., which aid in triggering the onset of the ailment, is also propelling the market growth. Besides this, the widespread adoption of immunosuppressive agents in conjunction with corticosteroids to control the immune system and prevent the formation of new blisters is creating a positive outlook for the market. Moreover, the emerging popularity of plasmapheresis for treating severe cases of disease that do not respond to other treatments is acting as another significant growth-inducing factor. This procedure is used to remove autoantibodies and other immune system components that contribute to the development of the ailment. Furthermore, the rising usage of indirect immunofluorescence for diagnosing the disorder, which involves using fluorescent antibodies to detect the presence of autoantibodies, is also augmenting the market growth. Apart from this, the escalating demand for intravenous immunoglobulin therapy among patients with refractory disease or who are unable to tolerate systemic corticosteroids is expected to drive the pemphigus vulgaris market during the forecast period.
This report provides an exhaustive analysis of the pemphigus vulgaris market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pemphigus vulgaris and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pemphigus vulgaris market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the pemphigus vulgaris market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the pemphigus vulgaris market
Competitive Landscape:
This report also provides a detailed analysis of the current pemphigus vulgaris marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the pemphigus vulgaris market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the pemphigus vulgaris market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the pemphigus vulgaris market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of pemphigus vulgaris across the seven major markets?
- What is the number of prevalent cases (2018-2034) of pemphigus vulgaris by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of pemphigus vulgaris by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with pemphigus vulgaris across the seven major markets?
- What is the size of the pemphigus vulgaris patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of pemphigus vulgaris?
- What will be the growth rate of patients across the seven major markets?
Pemphigus Vulgaris: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for pemphigus vulgaris drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pemphigus vulgaris market?
- What are the key regulatory events related to the pemphigus vulgaris market?
- What is the structure of clinical trial landscape by status related to the pemphigus vulgaris market?
- What is the structure of clinical trial landscape by phase related to the pemphigus vulgaris market?
- What is the structure of clinical trial landscape by route of administration related to the pemphigus vulgaris market?
Table of Contents
?1 Preface3 Executive Summary6 Patient Journey9 Pemphigus Vulgaris - Unmet Needs10 Pemphigus Vulgaris - Key Endpoints of Treatment13. Pemphigus Vulgaris - Attribute Analysis of Key Marketed and Pipeline Drugs16 Pemphigus Vulgaris - Recent Events and Inputs From Key Opinion Leaders18 Pemphigus Vulgaris Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Pemphigus Vulgaris - Introduction
5 Pemphigus Vulgaris - Disease Overview
7 Pemphigus Vulgaris - Epidemiology and Patient Population
8 Pemphigus Vulgaris - Treatment Algorithm, Guidelines, and Medical Practices
11 Pemphigus Vulgaris - Marketed Products
12 Pemphigus Vulgaris - Pipeline Drugs
14. Pemphigus Vulgaris - Clinical Trial Landscape
15 Pemphigus Vulgaris - Market Scenario
17 Pemphigus Vulgaris Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 132 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 265.3 Million |
| Forecasted Market Value ( USD | $ 519.4 Million |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
